Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Glatting

Showing results (31-40 of 150) with videos related to

Pageof 15
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|July 13, 2016
Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide TherapyDeni Hardiansyah, Nusrat Jihan Begum, Peter Kletting, et al.
Nuklearmedizin. Nuclear Medicine|November 2, 2020
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligandsNusrat Jihan Begum, Gerhard Glatting, Matthias Eiber, et al.
Zeitschrift Fur Medizinische Physik|April 9, 2013
Dependence of image quality on acquisition time for the PET/CT Biograph mCTFlavia Molina-Duran, Dietmar Dinter, Frederic Schoenahl, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|July 26, 2017
Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic modelDeni Hardiansyah, Ali Asgar Attarwala, Peter Kletting, et al.
EJNMMI Physics|April 8, 2025
Non-linear mixed-effects modelling and population-based model selection for <sup>131</sup>I kinetics in benign thyroid diseaseDeni Hardiansyah, Ade Riana, Heribert Hänscheid, et al.
Medical Physics|July 23, 2011
Optimal preloading in radioimmunotherapy with anti-cD45 antibodyPeter Kletting, Thomas Kull, Donald Bunjes, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2021
A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in RatsNouran R R Zaid, Peter Kletting, Gordon Winter, et al.
PET Clinics|October 22, 2025
An Overview of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Models: Applications to Radiopharmaceutical Therapies for Analysis and PersonalizationDeni Hardiansyah, Bisma Barron Patrianesha, Kuangyu Shi, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 15, 2015
Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody RadioimmunotherapyChristian Maaß, Peter Kletting, Donald Bunjes, et al.
EJNMMI Research|March 27, 2016
Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling scheduleChristian Maaß, Jan Philipp Sachs, Deni Hardiansyah, et al.
Pageof 15

Showing results (31-40 of 150) with videos related to

Sort By:
Pageof 15
Cancer Biotherapy & Radiopharmaceuticals|July 13, 2016
Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide TherapyDeni Hardiansyah, Nusrat Jihan Begum, Peter Kletting, et al.
Nuklearmedizin. Nuclear Medicine|November 2, 2020
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligandsNusrat Jihan Begum, Gerhard Glatting, Matthias Eiber, et al.
Zeitschrift Fur Medizinische Physik|April 9, 2013
Dependence of image quality on acquisition time for the PET/CT Biograph mCTFlavia Molina-Duran, Dietmar Dinter, Frederic Schoenahl, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|July 26, 2017
Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic modelDeni Hardiansyah, Ali Asgar Attarwala, Peter Kletting, et al.
EJNMMI Physics|April 8, 2025
Non-linear mixed-effects modelling and population-based model selection for <sup>131</sup>I kinetics in benign thyroid diseaseDeni Hardiansyah, Ade Riana, Heribert Hänscheid, et al.
Medical Physics|July 23, 2011
Optimal preloading in radioimmunotherapy with anti-cD45 antibodyPeter Kletting, Thomas Kull, Donald Bunjes, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2021
A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in RatsNouran R R Zaid, Peter Kletting, Gordon Winter, et al.
PET Clinics|October 22, 2025
An Overview of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Models: Applications to Radiopharmaceutical Therapies for Analysis and PersonalizationDeni Hardiansyah, Bisma Barron Patrianesha, Kuangyu Shi, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 15, 2015
Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody RadioimmunotherapyChristian Maaß, Peter Kletting, Donald Bunjes, et al.
EJNMMI Research|March 27, 2016
Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling scheduleChristian Maaß, Jan Philipp Sachs, Deni Hardiansyah, et al.
Pageof 15